• 1
    Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961964.
  • 2
    Boyer N, Marcellin P. Natural history of hepatitis C and the impact of anti-viral therapy. Forum (Genova) 2000; 10: 418.
  • 3
    Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31(Suppl 1): 916.
  • 4
    Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362369.
  • 5
    Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. HEPATOLOGY 1998; 27: 868872.
  • 6
    Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. HEPATOLOGY 2002; 36: 973977.
  • 7
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 8
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 9
    Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. HEPATOLOGY 2002; 36: 179184.
  • 10
    Zeuzem S, Diago M, Gane E, Reddy R, Pockros P, Prati D, et al. Peginterferon alfa-2a (40KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology, in press.
  • 11
    Kronenberger B, Ruster B, Lee JH, Sarrazin C, Roth WK, Herrmann G, et al. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol 2000; 33: 640647.
  • 12
    Rico MA, Quiroga JA, Subira D, Garcia E, Castanon S, Sallberg M, et al. Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. J Hepatol 2002; 36: 408416.
  • 13
    Asselah T, Martinot M, Cazals-Hatem D, Boyer N, Auperin A, Le Breton V, et al. Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. J Viral Hepat 2002; 9: 2935.
  • 14
    Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760764.
  • 15
    Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. HEPATOLOGY 2003; 37: 13511358.
  • 16
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103107.
  • 17
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 14381447.
  • 18
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981; 1: 431435.
  • 19
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 20
    Prati D, Taioli E, Zanella A, Della TE, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 110.
  • 21
    Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. HEPATOLOGY 2003; 37: 600609.
  • 22
    Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. HEPATOLOGY 2003; 37: 13591367.
  • 23
    Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. HEPATOLOGY 2003; 38: 509517.
  • 24
    Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9: 340345.
  • 25
    Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 2835.
  • 26
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003; 37: 13431350.
  • 27
    Tang KH, Herrmann E, Tatman N, Chokshi S, Cooksley H, Sablon E, et al. Relationship between early viral kinetics and immune reactivity in chronic hepatitis C (genotype 1) patients treated with peginterferon alfa 2a and ribavirin [abstract]. HEPATOLOGY 2003; 38(Suppl): 68A.
  • 28
    Haruna Y, Kanda T, Honda M, Takao T, Hayashi N. Detection of hepatitis C virus in the bile and bile duct epithelial cells of hepatitis C virus-infected patients. HEPATOLOGY 2001; 33: 977980.
  • 29
    Nouri Aria KT, Sallie R, Sangar D, Alexander GJ, Smith H, Byrne J, et al. Detection of genomic and intermediate replicative strands of hepatitis C virus in liver tissue by in situ hybridization. J Clin Invest 1993; 91: 22262234.
  • 30
    Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003; 49: 13581366.
  • 31
    Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003; 254: 287295.
  • 32
    Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38: 263355.
  • 33
    Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. HEPATOLOGY 2003; 38: 7585.